Royal Bank Of Canada Ascendis Pharma A/S Transaction History

Royal Bank Of Canada

$579 Billion
Q3 2025

A detailed history of Royal Bank Of Canada transactions in Ascendis Pharma A/S stock. As of the latest transaction made, Royal Bank Of Canada holds 7,188 shares of ASND stock, worth $1.47 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

7,188

Previous 1,723 317.18%

Holding current value

$1.47 Million

Previous $297,000 381.14%

% of portfolio

0.0%

Previous 0.0%

21 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2025 Nov 14, 2025	BUY	$163.32 - $205.91 $892,543 - $1.13 Million	5,465 Added 317.18%	7,188 $1.43 Million
Q2 2025 Nov 21, 2025	SELL	$137.41 - $179.1 $4.18 Million - $5.45 Million	-30,413 Reduced 94.64%	1,723 $297,000
Q2 2025 Aug 14, 2025	SELL	$137.41 - $179.1 $4.18 Million - $5.45 Million	-30,413 Reduced 94.64%	1,723 $297,000
Q1 2025 Nov 21, 2025	BUY	$119.49 - $168.84 $2.98 Million - $4.21 Million	24,948 Added 347.08%	32,136 $5.01 Million
Q1 2025 May 15, 2025	SELL	$119.49 - $168.84 $24,853 - $35,118	-208 Reduced 0.64%	32,136 $5.01 Million

Q4 2024 Feb 14, 2025	BUY	$122.0 - $146.6 $3.74 Million - $4.49 Million	30,617 Added 1772.84%	32,344 $4.45 Million
Q3 2024 Nov 14, 2024	SELL	$113.0 - $153.43 $646,134 - $877,312	-5,718 Reduced 76.8%	1,727 $257,000
Q2 2024 Aug 14, 2024	BUY	$121.07 - $153.67 $36,078 - $45,793	298 Added 4.17%	7,445 $1.02 Million
Q1 2024 Nov 05, 2024	SELL	$123.45 - $159.4 $36,788 - $47,501	-298 Reduced 4.0%	7,147 $1.08 Million
Q1 2024 May 15, 2024	SELL	$123.45 - $159.4 $35,553 - $45,907	-288 Reduced 3.87%	7,147 $1.08 Million
Q4 2023 Feb 14, 2024	BUY	$86.1 - $127.36 $49,249 - $72,849	572 Added 8.33%	7,435 $936,000
Q3 2023 Nov 14, 2023	SELL	$86.5 - $103.97 $272,475 - $327,505	-3,150 Reduced 31.46%	6,863 $642,000
Q2 2023 Aug 14, 2023	BUY	$69.96 - $97.84 $630,549 - $881,831	9,013 Added 901.3%	10,013 $893,000
Q1 2023 May 15, 2023	SELL	$104.9 - $126.78 $6,923 - $8,367	-66 Reduced 6.19%	1,000 $107,000
Q4 2022 Feb 14, 2023	SELL	$99.42 - $131.97 $43,446 - $57,670	-437 Reduced 29.08%	1,066 $130,000
Q3 2022 Nov 14, 2022	SELL	$84.03 - $110.23 $81,593 - $107,033	-971 Reduced 39.25%	1,503 $155,000
Q2 2022 Aug 15, 2022	BUY	$78.08 - $117.61 $6,636 - $9,996	85 Added 3.56%	2,474 $230,000
Q1 2022 May 16, 2022	BUY	$102.18 - $135.75 $74,795 - $99,369	732 Added 44.18%	2,389 $281,000
Q4 2021 Feb 14, 2022	SELL	$127.1 - $169.66 $64,693 - $86,356	-509 Reduced 23.5%	1,657 $223,000
Q3 2021 Nov 15, 2021	BUY	$112.67 - $176.92 $34,927 - $54,845	310 Added 16.7%	2,166 $345,000
Q2 2021 Aug 16, 2021	BUY	$121.62 - $145.29 $225,726 - $269,658	1,856 New	1,856 $244,000

Others Institutions Holding ASND

# of Institutions

318

Shares Held

65M

Call Options Held

476K

Put Options Held

142K

View Full List

About Ascendis Pharma A/S

Ticker ASND
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,810,200
Market Cap $11.4B
Description
Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapeutics for unmet medical needs. The company offers SKYTROFA for treating patients with growth hormone deficiency (GHD). It also develops TransCon Growth Hormone (hGH) for pediatric GHD in Japan; TransCon hGH for adults with GHD; TransCon parathyroid hormone for adult h...

More about ASND

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Royal Bank Of Canada, based on Form 13F filings with the SEC.

News

Stay updated on Royal Bank Of Canada with notifications on news.

Account

Royal Bank Of Canada Ascendis Pharma A/S Transaction History